The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Open accessAbstract
Acetyl coenzyme A (AcCoA) is the central biosynthetic precursor for fatty-acid synthesis and protein acetylation. In the conventional view of mammalian cell metabolism, AcCoA is primarily generated from glucose-derived pyruvate through the citrate shuttle and ATP citrate lyase in the cytosol. However, proliferating cells that exhibit aerobic glycolysis and those exposed to hypoxia convert glucose to lactate at near-stoichiometric levels, directing glucose carbon away from the tricarboxylic acid cycle and fatty-acid synthesis. Although glutamine is consumed at levels exceeding that required for nitrogen biosynthesis, the regulation and use of glutamine metabolism in hypoxic cells is not well understood. Here we show that human cells use reductive metabolism of α-ketoglutarate to synthesize AcCoA for lipid synthesis. This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is active in most cell lines under normal culture conditions, but cells grown under hypoxia rely almost exclusively on the reductive carboxylation of glutamine-derived α-ketoglutarate for de novo lipogenesis. Furthermore, renal cell lines deficient in the von Hippel-Lindau tumour suppressor protein preferentially use reductive glutamine metabolism for lipid biosynthesis even at normal oxygen levels. These results identify a critical role for oxygen in regulating carbon use to produce AcCoA and support lipid synthesis in mammalian cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both HIF-1α and HIF-2α activation promotes the upregulation of the glutamine transporter, SLC38A2, which increases the dependency of cells to glutamine and correlates with poorer survival in patients with breast cancer [58]”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of constitutive HIF-2α stabilization75 or a defective mitochondrial electron transport chain76, glutamine-derived α-KG is reductively carboxylated through the consumption of NADPH by IDH2 to generate citrate.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although oxidation of glutamine-derived α-KG in the TCA cycle serves as a minor source of lipogenic acetyl-CoA under normal growth conditions, α-KG can be converted to citrate through reductive carboxylation under conditions of stress such as hypoxia or mitochondrial dysfunction (70–72).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, checkpoint kinase 1 (CHK1) inhibitors625–627 and glutaminase (GLS) inhibitors628–634 are also considered potential candidates for treating Myc-overexpressing cancers.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [631]
In the citing paper
“Citrate, generated by reductive carboxylation of α-KG, is especially crucial for lipid synthesis under low-oxygen conditions24,25.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [24]
In the citing paper
“and switch the fate of glutamine from the oxidative pathway into the reductive carboxylation pathway24.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [24]
In the citing paper
“Glutamine acts as an alternative fuel for fatty acid synthesis, supplying citrate via mitochondrial reductive carboxylation, especially under hypoxic conditions74,75.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [75]
In the citing paper
“Alternatively, proliferating cells under hypoxia have been reported to predominantly reductively carboxylate glutamine generated α-ketoglutarate through IDH 1/2 to generate M5 citrate (Figure 4A) (Metallo, 2012).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“Previous reports showed that reductive carboxylation is a critical pathway to support the growth of tumor cells under hypoxia (Metallo, 2012; Mullen, 2012).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“The upregulation of the reductive carboxylation pathway enhances cancer cells proliferation (Metallo, 2012; Mullen, 2012; Wise et al., 2011).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“For example, under conditions of hypoxia or impaired mitochondrial respiration, certain reactions of the TCA cycle reverse to support glutamine-dependent reductive carboxylation (92, 122, 123).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [122]
In the citing paper
“In a process referred to as reductive carboxylation, a section of the TCA cycle reverses itself, converting α-ketoglutarate into citrate, which can be then used to generate a source of cytosolic acetyl-CoA (Metallo et al., 2012; Wise et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Metallo et al., 2012
In the citing paper
“Citrate is generated by citrate synthase (CS) or through the reduction of α-ketoglutarate by isocitrate dehydrogenase (IDH).79–81”
From The multifaceted contributions of mitochondria to cellular metabolism (2018) · cites this paper as [79]
In the citing paper
“Citrate levels, however, were markedly decreased in Mpc1KD or Mpc2KD (Mpc1/2KD) cells, as this metabolite is generated predominantly from pyruvate-derived AcCoA under normal growth conditions (Metallo et al., 2012).”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“Glutamine can contribute carbon to fatty acid synthesis via reductive carboxylation or oxidative glutaminolysis.”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“The former pathway is highly active in cells proliferating under hypoxia or those with a compromised respiratory chain (Metallo et al., 2012; Mullen et al., 2012; Scott et al., 2011; Wise et al., 2011), while the latter pathway has been observed in B cell lymphoma (Le et al., 2012).”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“This switch to reductive versus oxidative metabolism of α-KG is regulated in part by HIF-1α (71, 72), although the exact mechanism by which HIF-1α does so remains unclear.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“The work from Metallo and colleagues (71) suggests that T cells can use reductive glutamine metabolism for fatty acid biosynthesis under hypoxic conditions.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“In place of oxidative metabolism of both glucose and glutamine, these cancers preferentially perform reductive and carboxylating biosynthetic reactions from glutamine carbon (Le et al., 2012; Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Metallo et al., 2012
In the citing paper
“Recently three independent reports implicated IDH-dependent reductive carboxylation as playing a particularly important role in proliferating cells that exhibit decreased flux of glucose-derived pyruvate into the mitochondria. This occurs in hypoxic cells or in cells harboring defects in mitochondrial oxidative phosphorylation (Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Metallo et al., 2012
In the citing paper
“tumor cells with mutations in the TCA cycle or ETC (Mullen et al., 2011), or with hypoxia-induced suppression of oxidative metabolism (Metallo et al., 2011; Scott et al., 2011; Wise et al., 2011) use reductive carboxylation of α-KG to produce citrate and other precursors during growth.”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Metallo et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The von Hippel–Lindau (VHL) tumour suppressor protein is frequently lost in renal cell carcinoma (RCC) and results in a state of ‘pseudohypoxia’ by activating HIF signallin”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Cited by
Sorted by citations
Items 401–500 of 1,003
The Yeast Retrograde Response as a Model of Intracellular Signaling of Mitochondrial Dysfunction
Jazwinski, S. M., & Kriete, A. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00139 · Cited by 119
Amino acid management in cancer
Tsun, Z.-Y., & Possemato, R. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.08.002 · Cited by 120
Hominoid-specific enzyme GLUD2 promotes growth of IDH1 R132H glioma
Chen, R., Nishimura, M. C., Kharbanda, S., Peale, F., Deng, Y., Daemen, A., Forrest, W. F., Kwong, M., Hedehus, M., Hatzivassiliou, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409653111 · Cited by 112
Damiani, C., Colombo, R., Gaglio, D., Mastroianni, F., Pescini, D., Westerhoff, H. V., Mauri, G., Vanoni, M., & Alberghina, L. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005758 · Cited by 110
Role of Metabolic Reprogramming in Pulmonary Innate Immunity and Its Impact on Lung Diseases
Michaeloudes, C., Bhavsar, P. K., Mumby, S. E., Xu, B., Hui, C., Chung, K. F., & Adcock, I. M. (2019) · Journal of Innate Immunity · doi:10.1159/000504344 · Cited by 115
Profiling metabolic networks to study cancer metabolism
Hiller, K., & Metallo, C. M. (2012) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.11.001 · Cited by 113
Self-citationHallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming
D’Alessandro, A., Kasmi, K. C. E., Plecitá‐Hlavatá, L., Ježek, P., Li, M., Zhang, H., Gupte, S. A., & Stenmark, K. R. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7217 · Cited by 111
Vučetić, M., Cormerais, Y., Parks, S. K., & Pouysségur, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00319 · Cited by 121
Glutamine‐fueled mitochondrial metabolism is decoupled from glycolysis in melanoma
Filipp, F. V., Ratnikov, B. I., Ingeniis, J. D., Smith, J. W., Osterman, A. L., & Scott, D. A. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12000 · Cited by 115
Metabolism and epigenetics: a link cancer cells exploit
Carrer, A., & Wellen, K. E. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.11.012 · Cited by 110
Coactivator SRC-2–dependent metabolic reprogramming mediates prostate cancer survival and metastasis
Dasgupta, S., Putluri, N., Long, W., Zhang, B., Wang, J., Kaushik, A., Arnold, J. M., Bhowmik, S. K., Stashi, E., Brennan, C. A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76029 · Cited by 112
Endothelial cell metabolism: parallels and divergences with cancer cell metabolism
Verdegem, D., Moens, S., Stapor, P. C., & Carmeliet, P. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-19 · Cited by 117
Porporato, P. E., Payen, V. L., Baselet, B., & Sonveaux, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2100-2 · Cited by 115
Biochemistry of proinflammatory macrophage activation
Nonnenmacher, Y., & Hiller, K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2784-1 · Cited by 112
Self-citationReversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells
Zheng, L., MacKenzie, E. D., Karim, S. A., Hedley, A., Blyth, K., Kalna, G., Watson, D. G., Szlosarek, P., Frezza, C., & Gottlieb, E. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-12 · Cited by 103
Current and future perspectives of functional metabolomics in disease studies–A review
Yan, M., & Xu, G. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.04.006 · Cited by 105
Talati, M. H., & Hemnes, A. R. (2015) · Pulmonary Circulation · doi:10.1086/681227 · Cited by 106
Kaminska, B., Czapski, B., Guzik, R., Król, S. K., & Gielniewski, B. (2019) · Molecules · doi:10.3390/molecules24050968 · Cited by 114
Capitanio, D., Moriggi, M., Torretta, E., Barbacini, P., Palma, S. D., Viganò, A., Lochmüller, H., Muntoni, F., Ferlini, A., Mora, M., et al. (2020) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12527 · Cited by 108
Global Profiling of Metabolic Adaptation to Hypoxic Stress in Human Glioblastoma Cells
Kucharzewska, P., Christianson, H. C., & Belting, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116740 · Cited by 107
Targeting glucose metabolism in patients with cancer
Elf, S., & Chen, J. (2013) · Cancer · doi:10.1002/cncr.28501 · Cited by 108
A conserved phosphatase destroys toxic glycolytic side products in mammals and yeast
Collard, F., Baldin, F., Gerin, I., Bolsée, J., Noël, G., Graff, J., Veiga‐da‐Cunha, M., Stroobant, V., Vertommen, D., Houddane, A., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2104 · Cited by 103
Cancer heterogeneity is not compatible with one unique cancer cell metabolic map
Strickaert, A., Saiselet, M., Dom, G., Deken, X. D., Dumont, J. E., Féron, O., Sonveaux, P., & Maenhaut, C. (2016) · Oncogene · doi:10.1038/onc.2016.411 · Cited by 111
Okazaki, A., Gameiro, P. A., Christodoulou, D. C., Laviolette, L. A., Schneider, M., Chaves, F. L., Stemmer-Rachamimov, A. O., Yazinski, S. A., Lee, R. E., Jr., Stephanopoulos, G. N., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87800 · Cited by 110
Self-citationMetabolomics and Metabolic Reprogramming in Kidney Cancer
Weiss, R. H. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.01.006 · Cited by 110
Mitochondrial Respiration - An Important Therapeutic Target in Melanoma
de Moura, M. B., Vincent, G., Fayewicz, S. L., Bateman, N. W., Hood, B. L., Sun, M., Suhan, J. P., Duensing, S. M., Yin, Y., Sander, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040690 · Cited by 105
The Metabolic Alterations of Cancer Cells
Sciacovelli, M., Gaude, E., Hilvo, M., & Frezza, C. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00001-7 · Cited by 108
The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
Smolková, K., & Ježek, P. (2012) · International Journal of Cell Biology · doi:10.1155/2012/273947 · Cited by 114
New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
Srinivasan, R., Ricketts, C. J., Sourbier, C., & Linehan, W. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2993 · Cited by 111
How metabolites modulate metabolic flux
Wegner, A., Meiser, J., Weindl, D., & Hiller, K. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.11.008 · Cited by 108
Self-citationVitamin D endocrinology on the cross-road between immunity and metabolism
Vanherwegen, A.-S., Gysemans, C. A., & Mathieu, C. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.04.018 · Cited by 107
Kidney tissue hypoxia dictates T cell–mediated injury in murine lupus nephritis
Chen, P.-M., Wilson, P. C., Shyer, J. A., Veselits, M., Steach, H. R., Cui, C., Moeckel, G. W., Clark, M. R., & Craft, J. E. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1620 · Cited by 103
Amino Acid Metabolism in Cancer Drug Resistance
Yoo, H.-C., & Han, J. M. (2022) · Cells · doi:10.3390/cells11010140 · Cited by 107
Bonanomi, M., Salmistraro, N., Porro, D., Pinsino, A., Colangelo, A. M., & Gaglio, D. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.134947 · Cited by 110
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Dimitrov, L., Hong, C. S., Yang, C., Zhuang, Z., & Heiss, J. D. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11047 · Cited by 108
TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma
Todisco, S., Convertini, P., Iacobazzi, V., & Infantino, V. (2019) · Cancers · doi:10.3390/cancers12010068 · Cited by 105
Reductive carboxylation epigenetically instructs T cell differentiation
Jaccard, A., Wyss, T., Maldonado‐Pérez, N., Rath, J. A., Bevilacqua, A., Peng, J.-J., Lepez, A., Gunten, C. V., Franco, F., Kao, K., et al. (2023) · Nature · doi:10.1038/s41586-023-06546-y · Cited by 105
Yang, Y., Lane, A. N., Ricketts, C. J., Sourbier, C., Wei, M.-H., Shuch, B. M., Pike, L. S., Wu, M., Rouault, T. A., Boros, L. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072179 · Cited by 104
Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM)
Bruntz, R. C., Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.776054 · Cited by 107
The role of glutamate and glutamine metabolism and related transporters in nerve cells
Zhang, D., Hua, Z., & Li, Z. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14617 · Cited by 113
Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery
Denkert, C., Bucher, E., Hilvo, M., Salek, R. M., Orešič, M., Griffin, J. L., Brockmöller, S. F., Klauschen, F., Loibl, S., Barupal, D. K., et al. (2012) · Genome Medicine · doi:10.1186/gm336 · Cited by 101
Predicting Drug Targets and Biomarkers of Cancer via Genome-Scale Metabolic Modeling
Jerby‐Arnon, L., & Ruppin, E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1856 · Cited by 102
Linking vitamin B1 with cancer cell metabolism
Zastre, J. A., Sweet, R. L., Hanberry, B. S., & Ye, S. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-16 · Cited by 103
Aberrant lipid metabolism as an emerging therapeutic strategy to target cancer stem cells
Visweswaran, M., Arfuso, F., Warrier, S. R., & Dharmarajan, A. (2019) · Stem Cells · doi:10.1002/stem.3101 · Cited by 101
Mechanisms underlying the health benefits of intermittent hypoxia conditioning
Burtscher, J., Citherlet, T., Camacho-Cardeñosa, A., Camacho-Cardeñosa, M., Raberin, A., Krumm, B., Hohenauer, E., Egg, M., Lichtblau, M., Müller, J., et al. (2023) · The Journal of Physiology · doi:10.1113/jp285230 · Cited by 132
Deep, G., & Schlaepfer, I. R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071061 · Cited by 101
Jiang, Q., Qiu, Y., Kurland, I. J., Drlica, K., Subbian, S., Tyagi, S., & Shi, L. (2022) · mBio · doi:10.1128/mbio.01274-22 · Cited by 98
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1978-z · Cited by 99
Gabra, M. B. I., Yang, Y., Li, H., Senapati, P., Hanse, E. A., Lowman, X. H., Tran, T. Q., Zhang, L., Doan, L. T., Xu, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17181-w · Cited by 99
Aberrant lipid metabolism in cancer cells – the role of oncolipid‐activated signaling
Ray, U., & Roy, S. S. (2017) · FEBS Journal · doi:10.1111/febs.14281 · Cited by 96
Regulation and targeting of SREBP-1 in hepatocellular carcinoma
Su, F., & Koeberle, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10156-5 · Cited by 107
A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia
Adam, J., Yang, M., Bauerschmidt, C., Kitagawa, M., O’Flaherty, L., Maheswaran, P., Özkan, G., Sahgal, N., Baban, D., Kato, K., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.006 · Cited by 97
Mitochondrial DNA mutations and breast tumorigenesis
Yadav, N., & Chandra, D. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.10.002 · Cited by 96
Bian, X., Li, N., Tan, B., Sun, B., Guo, M., Huang, G., Fu, L., Hsiao, W. L. W., Liu, L., & Wu, J. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b01873 · Cited by 97
Metabolic Plasticity of Tumor Cell Mitochondria
Cannino, G., Ciscato, F., Masgras, I., Sànchez‐Martìn, C., & Rasola, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00333 · Cited by 97
Glutamine Metabolism in Brain Tumors
Natarajan, S. K., & Venneti, S. (2019) · Cancers · doi:10.3390/cancers11111628 · Cited by 99
Lanning, N. J., Looyenga, B. D., Kauffman, A. L., Niemi, N. M., Sudderth, J., DeBerardinis, R. J., & MacKeigan, J. P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.065 · Cited by 94
Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations
Ansari, R. E., McIntyre, A., Craze, M. L., Ellis, I. O., Rakha, E. A., & Green, A. R. (2017) · Histopathology · doi:10.1111/his.13334 · Cited by 93
Metabolomics, metabolic flux analysis and cancer pharmacology
Liang, L., Sun, F., Wang, H., & Hu, Z. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107827 · Cited by 99
Ushio‐Fukai, M., Ash, D., Nagarkoti, S., de Chantemèle, E. J. B., Fulton, D. J., & Fukai, T. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8161 · Cited by 99
Mitochondrial DNA mutations in ageing and cancer
Smith, A. L. M., Whitehall, J. C., & Greaves, L. C. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13291 · Cited by 105
Glutamine addiction in tumor cell: oncogene regulation and clinical treatment
Li, X., Peng, X., Li, Y., Wei, S., He, G., Liu, J., Li, X., Yang, S., Dai, L., Lin, W., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01449-x · Cited by 103
Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review
Fakhri, S., Moradi, S. Z., Farzaei, M. H., & Bishayee, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.007 · Cited by 97
Tracing insights into de novo lipogenesis in liver and adipose tissues
Wallace, M., & Metallo, C. M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.02.012 · Cited by 94
Self-citationHao, X., Ren, Y., Feng, M., Wang, Q., & Wang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111798 · Cited by 101
HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis
Meléndez‐Rodríguez, F., Urrutia, A. A., Lorendeau, D., Rinaldi, G., Roche, O., Böğürcü, N., Ortega‐Muelas, M., Mesa‐Ciller, C., Turiel, G., Bouthelier, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.106 · Cited by 99
Hypoxia Mediates Tumor Malignancy and Therapy Resistance
Luo, W., & Wang, Y. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_1 · Cited by 94
Cheng, G., Zielonka, J., McAllister, D. M., Tsai, S., Dwinell, M. B., & Kalyanaraman, B. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.272 · Cited by 90
13C metabolic flux analysis at a genome-scale
Gopalakrishnan, S., & Maranas, C. D. (2015) · Metabolic Engineering · doi:10.1016/j.ymben.2015.08.006 · Cited by 92
Lim, J.-H., Luo, C., Vazquez, F., & Puigserver, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2893-t · Cited by 96
Hopperton, K. E., Duncan, R. E., Bazinet, R. P., & Archer, M. C. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.10.016 · Cited by 91
Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells
Murphy, T. A., Dang, C. V., & Young, J. D. (2012) · Metabolic Engineering · doi:10.1016/j.ymben.2012.07.008 · Cited by 92
Hulea, L., Gravel, S., Morita, M., Cargnello, M., Uchenunu, O., Im, Y. K., Lehuédé, C., Ma, E. H., Leibovitch, M., McLaughlan, S., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.001 · Cited by 91
Brain stem cells as the cell of origin in glioma
Modrek, A. S. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i1.43 · Cited by 90
Understanding metabolism with flux analysis: From theory to application
Dai, Z., & Locasale, J. W. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.09.005 · Cited by 92
Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
Alzial, G., Renoult, O., Paris, F., Gratas, C., Clavreul, A., & Pecqueur, C. (2021) · Oncogene · doi:10.1038/s41388-021-02056-1 · Cited by 101
Liu, L., Ning, X.-X., Wei, L., Zhou, Y., Zhao, L.-J., Ma, F., Bai, M., Yang, X.-X., Wang, D., & Sun, S.-R. (2022) · Theranostics · doi:10.7150/thno.71722 · Cited by 82
ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming
Mishra, P., Tang, W., Putluri, V., Dorsey, T. H., Jin, F., Wang, F., Zhu, D., Amable, L., Deng, T., Zhang, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93815 · Cited by 91
Reitman, Z. J., Duncan, C. G., Poteet, E. C., Winters, A., Yan, L., Gooden, D. M., Spasojević, I., Boros, L. G., Yang, S.-H., & Yan, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.575183 · Cited by 93
Li, G., Li, M., Hu, J., Lei, R., Xiong, H., Ji, H., Yin, H., Wei, Q., & Hu, G. (2016) · Oncogene · doi:10.1038/onc.2016.265 · Cited by 86
Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer
Bhardwaj, V., & He, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103412 · Cited by 88
Advancing Cancer Treatment by Targeting Glutamine Metabolism—A Roadmap
Halama, A., & Suhre, K. (2022) · Cancers · doi:10.3390/cancers14030553 · Cited by 93
Blockage of citrate export prevents TCA cycle fragmentation via Irg1 inactivation
Li, Y., Li, Y., Liu, X.-T., Zhang, L., Chen, Y.-H., Zhao, Q., Gao, W. Y., Liu, B., Yang, H. Q., & Li, P. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110391 · Cited by 88
Morten, K., Badder, L. M., & Knowles, H. J. (2013) · The Journal of Pathology · doi:10.1002/path.4159 · Cited by 91
Rare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 90
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 92
Activated lymphocytes as a metabolic model for carcinogenesis
Macintyre, A. N., & Rathmell, J. C. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-5 · Cited by 93
Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells
Bernfeld, E., & Foster, D. A. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.03.003 · Cited by 85
Yang, S.-H., Li, W., Sumien, N., Forster, M. J., Simpkins, J. W., & Liu, R. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.005 · Cited by 89
Icard, P., & Lincet, H. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.09.003 · Cited by 86
Akt and STAT5 mediate naïve human CD4+ T-cell early metabolic response to TCR stimulation
Jones, N., Vincent, E. E., Cronin, J., Panetti, S., Chambers, M., Holm, S. R., Owens, S. E., Francis, N., Finlay, D. K., & Thornton, C. A. (2019) · Nature Communications · doi:10.1038/s41467-019-10023-4 · Cited by 88
Joly, J. H., Delfarah, A., Phung, P. S., Parrish, S., & Graham, N. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011471 · Cited by 88
Stalnecker, C. A., Ulrich, S. M., Li, Y., Ramachandran, S., McBrayer, M. K., DeBerardinis, R. J., Cerione, R. A., & Erickson, J. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414056112 · Cited by 87
Genetically-defined metabolic reprogramming in cancer
Mullen, A. R., & DeBerardinis, R. J. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.06.009 · Cited by 90
IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma
Esmaeili, M., Hamans, B. C., Navis, A. C., van Horssen, R., Bathen, T. F., Gribbestad, I. S., Leenders, W. P. J., & Heerschap, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0008 · Cited by 86
Targeting extracellular nutrient dependencies of cancer cells
García‐Bermúdez, J., Williams, R. T., Guarecuco, R., & Birsoy, K. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.011 · Cited by 93
Gohar, A. V., Cassel, J. A., Mohammed, F. S., Zarei, M., Hue, J. J., Hajihassani, O., Graor, H. J., Srikanth, Y. V. V., Karim, S. A., Abbas, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00393-y · Cited by 89
Acetyl-CoA synthetase 2(ACSS2): a review with a focus on metabolism and tumor development
Ling, R., Chen, G., Tang, X., Liu, N., Zhou, Y., & Chen, D. (2022) · Discover Oncology · doi:10.1007/s12672-022-00521-1 · Cited by 95
T lymphocyte regulation by mevalonate metabolism
Thurnher, M., & Gruenbacher, G. (2015) · Science Signaling · doi:10.1126/scisignal.2005970 · Cited by 85
Du, J., Cleghorn, W. M., Contreras, L., Lindsay, K. J., Rountree, A. M., Chertov, A. O., Turner, S. J., Sahaboglu, A., Linton, J., Sadı́lek, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.507285 · Cited by 86
Metadata
- Authors
- Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., Kelleher, J. K., Vander Heiden, M. G., Iliopoulos, O., & Stephanopoulos, G.
- Affiliations
- Massachusetts Institute of Technology (US)
- Massachusetts General Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Iliopoulos, Othon
- Stephanopoulos, Gregory
- ORCID
- Venue
- Nature
- Published
- 2011-11-20
- Volume
- 481
- Issue
- 7381
- Pages
- 380-384
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3710581
- OpenAlex
- W2116516144
- Cited by
- 1,791
- References
- 43
- Citations by year
- 2026: 82 · 2025: 95 · 2024: 96 · 2023: 137 · 2022: 156 · 2021: 143 · 2020: 149 · 2019: 125 · 2018: 100 · 2017: 135 · 2016: 129 · 2015: 125 · 2014: 119 · 2013: 112 · 2012: 84
- FWCI
- 34.61
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- RePEc: Research Papers in Economics (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Damon Runyon Cancer Research Foundation
- Wellcome Trust
- Agios Pharmaceuticals
- National Institutes of Health
- National Cancer Institute (R01CA160458, R01CA122591, P30CA014051)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK075850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- IDH1, lipogenesis, hypoxia, reductive carboxylation, alpha-ketoglutarate, acetyl-CoA, fatty acid synthesis, VHL, renal cell carcinoma, cancer metabolism, mitochondrial dysfunction, aerobic glycolysis
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Acetyl Coenzyme A, Carbon, Carcinoma, Renal Cell, Cells, Cultured, Citric Acid Cycle, Glutamine, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Kidney Neoplasms, Oxidation-Reduction, Oxygen, Cell Hypoxia, CD8-Positive T-Lymphocytes, Palmitic Acid, Cell Line, Tumor, Lipogenesis, Aryl Hydrocarbon Receptor Nuclear Translocator, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
